BullMarket.com Updates Outlooks on CRO Stocks

PRINCETON, N.J., Feb. 8  /PRNewswire/ -- BullMarket.com (http://www.bullmarket.com/), an online investment newsletter focused on long-term growth and income-generating stocks, has provided subscribers with coverage of clinical research organization (CRO) stocks, including Covance (NYSE:CVD), Parexel (NASDAQ:PRXL), Charles River Laboratories (NYSE:CRL), Pharmaceutical Product Development (NASDAQ:PPDI), and Kendle International (NASDAQ:KNDL).

All paid and trial subscribers to BullMarket.com can now receive immediate access to the newsletter's exclusive daily reports. As a subscriber, you'll also gain access to our Recommended List of stocks, which was up 40% in 2009 and also outperformed the S&P by 15% in 2008.

  Start your 14-day free trial today:

  https://www.bullmarket.com/subscribe/pr/?refer=BMR687P



In its daily report, BullMarket.com wrote: "Covance CEO Joseph Herring conceded that 2009 was a difficult year, but he argued that the company made positive progress on many fronts. He cited its 11% revenue growth on a constant currency basis; its solid book-to-bill ratio; and market share gains across the board. He also noted Covance's successful integration of the Greenfield lab, which analysts generally consider to have been a good deal for the company."

  BullMarket.com looked at the following topics, among others:

  -- At what price would BullMarket.com be buyers of Covance's stock?

  -- Why has Parexel's outlook been stronger than many of its peers?



-- Why does Pharmaceutical Product Development look well positioned to rebound in the second half of the year?

-- Why would BullMarket.com currently be staying on the sidelines with Charles Rivers and Kendle?

About BullMarket.com:

Launched in 1997, BullMarket.com has a strong track record of creating wealth for its subscribers by providing sound, long-term investing advice. The BullMarket.com Recommended List includes about 50 companies across all major industries, including Financials, Healthcare, Energy, Technology, and Retail, among others. BullMarket.com is one of the oldest continuously published investment newsletters online, and its Recommended List has consistently outperformed the major market indices.

NOTE: This release was published by Indie Research Advisors, LLC, a registered investment advisor with CRD #131926. Interested parties may visit adviserinfo.sec.gov for additional information. Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

  Contact:

  Indie Research Advisors, LLC

  Marcie Martin, [phone]


DATASOURCE: Indie Research Advisors, LLC



CONTACT:  Marcie Martin, Indie Research Advisors, LLC, [phone]



Web Site:  http://www.bullmarket.com/ 

Copyright